Ceftazidime-avibactam for the treatment of Pseudomonas aeruginosa: a plain language summary
1
Issued Date
2025-01-01
Resource Type
ISSN
17460913
eISSN
17460921
Scopus ID
2-s2.0-105001990607
Journal Title
Future Microbiology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Future Microbiology (2025)
Suggested Citation
Kiratisin P., Kempf M., Stone G., Utt E. Ceftazidime-avibactam for the treatment of Pseudomonas aeruginosa: a plain language summary. Future Microbiology (2025). doi:10.1080/17460913.2025.2479967 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109488
Title
Ceftazidime-avibactam for the treatment of Pseudomonas aeruginosa: a plain language summary
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Plain Language Summary: What is this summary about? Pseudomonas aeruginosa (P. aeruginosa) is a type of bacteria that can make people ill. There are only a few medicines or drugs that can be used to treat illness caused by P. aeruginosa that is resistant to multiple drugs (such as multidrug resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa). This summary is about a study that collected P. aeruginosa samples (isolates) from patients across the world and tested medicines, including ceftazidime avibactam (CAZ-AVI), for their ability to stop the growth of P. aeruginosa samples in the laboratory (meaning, in a test tube). What are the key takeaways? 29,746 P. aeruginosa samples were collected globally from various regions (Latin America, Europe, Middle East, Africa, Asia Pacific, and North America). Of these: About 21% were multidrug resistant About 21% were extensively drug resistant About 8% were CAZ-AVI resistant, meaning CAZ-AVI could not stop the growth of these isolates. The highest proportion of resistant isolates was found in Latin America. CAZ-AVI was able to stop the growth of most P. aeruginosa (susceptibility 91%, meaning 9 in 10 bacteria could not grow in the presence of the drug). For multidrug resistant and extensively drug-resistant P. aeruginosa isolates, CAZ-AVI showed lower activity against resistant isolates (susceptibility 61% or less) compared to P. aeruginosa isolates overall. The only other medicines that could stop the growth of most P. aeruginosa were colistin (susceptibility 99%) and amikacin (susceptibility 91%). However, colistin was the only other drug capable of stopping the growth of most multidrug resistant and extensively drug-resistant P. aeruginosa isolates (susceptibility 98% or more). Amikacin had lower activity (susceptibility 61% or less) against resistant P. aeruginosa isolates compared to P. aeruginosa isolates overall. What were the main conclusions reported by the researchers? CAZ-AVI stopped the growth of most P. aeruginosa. CAZ-AVI can be used to treat illness caused by P. aeruginosa. It is important to monitor the spread of P. aeruginosa, including resistant isolates, and to keep checking whether medicines such as CZ-AVI can stop the growth of these isolates so that infections caused by these isolates can be treated effectively This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.